Financial Statements

Coherus BioSciences, Inc. (CHRS)

$7.66

+0.25 (+3.37%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -763-895-985-775-
Net Income -28713290-209-238
Stock Dividends -----537
Dividend Paid -----
Retained Earnings -1,050-763-895-985-775

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 2016713-
Annual Depreciation -111123-517
Capital Expenditure -1-7-13-1-5
Net PPE 82016713

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -1111
New Purchases -74-43-20-274-182
Intangible and Goodwill 11111

Coherus BioSciences, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Coherus BioSciences, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.